

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-74. (Canceled).

75. (Currently amended) A method for treating ~~an autoimmune~~ ~~a heat shock protein-alpha (2) macroglobulin (HSP-α2M) receptor-related~~ disorder comprising administering to a mammal having an ~~autoimmune~~ ~~HSP-α2M receptor-related~~ disorder an anti-CD91 antibody that binds alpha (2) macroglobulin receptor in an amount effective to treat the ~~autoimmune~~ ~~HSP-α2M receptor-related~~ disorder in the mammal, ~~provided that the HSP-α2M receptor-related disorder is not Alzheimer's disease, and wherein the HSP-α2M receptor-related disorder is an autoimmune disorder.~~

76-96. (Canceled)

97. (Previously presented) The method of claim 75, wherein the antibody interferes with the interaction of the alpha (2) macroglobulin receptor with a heat shock protein.

98. (Canceled)

99. (Previously presented) The method of claim 97, wherein the heat shock protein is gp96.

100. (Previously presented) The method of claim 97, wherein the heat shock protein is Hsp70.

101. (Previously presented) The method of claim 97, wherein the heat shock protein is Hsp90.

102-110. (Canceled)

111. (Previously presented) The method of claim 75, wherein the anti-CD91 antibody interferes with the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin.

112. (Previously presented) The method of claim 111, wherein the autoimmune disorder is selected from the group consisting of: insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura, rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility, Goodpasture's disease, bullous pemphigoid, discoid lupus, ulcerative colitis, or dense deposit disease.

113-121. (Cancelled)

122. (Previously presented) The method of claim 75, 97, 99-101, 111, or 112 wherein the anti-CD91 antibody is an antagonist of the alpha (2) macroglobulin receptor.

123-128. (Cancelled)

129. (Previously presented) The method of any one of claims 75, 97, 99-101, 111, or 112 wherein the mammal is a human.

130-131. (Cancelled)

132. (Previously presented) The method of any one of claims 75, 97, 99-101, or 111, or 112, wherein the antibody is purified.

133-147. (Cancelled)